9 November 2020

• Pfizer issues a press release with early data from its 43,538-person phase III coronavirus vaccine trial. Although details were limited, the company announced that the two-dose vaccine – which must be shipped and stored at ultra-cool temperatures (-70 degrees Celsius or -94°F )- has been 90% effective at preventing COVID-19 by seven days after the second dose. A total of 94 study participants became infected with coronavirus, which translates to nine infections in the vaccine group versus 84 in the placebo group. The company is collecting additional data and plans to submit it to the US FDA to obtain EUA in the coming weeks. Source
• US surpasses 10 million coronavirus cases just 10 days after reaching 9 million cases. Source
• President Trump accuses Pfizer of delaying trial results for political purposes, saying in a tweet that “The @US_FDA and the Democrats didn’t want to have me get a Vaccine WIN, prior to the election, so instead it came out five days later — As I’ve said all along!”

Return to the timeline